Clinical Trials

44 enrolled

Rectal Cancer Patients

NCT07444918 2026-03-03

Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors

33 enrolled

Sarcoma

Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT07123441 2025-08-14

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

300 enrolled

Colorectal Neoplasms

NCT07085273 2025-07-31

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

33 enrolled

Phase 1 Not yet recruiting

Stomach Neoplasms

NCT07060014 2025-07-11

NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers

22 enrolled

Advanced Small Intestine Cancer

NCT07028424 2025-07-01

PANORAMIX

206 enrolled

PDAC - Pancreatic Ductal Adenocarcinoma

NCT07004712 2025-06-08

Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

Phase 1 Not yet recruiting

46 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06710821 2024-11-29

Irinotecan Liposomes Combined with Temozolomide and Vincristine in the Treatment of Pediatric Patients with Solid Tumors

40 enrolled

Other solid neoplasm

Solid Tumor Cancer

NCT06700603 2024-11-22

Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer

48 enrolled

Pancreatic Neoplasms

NCT06697366 2024-11-20

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

27 enrolled

Phase 3 Not yet recruiting

Stomach Neoplasms

NCT06571461 2024-08-27

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

408 enrolled

Pancreatic Neoplasms

NCT06341309 2024-08-09

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

20 enrolled

Colorectal Neoplasms

NCT06513455 2024-07-22

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

132 enrolled

Phase 3 Not yet recruiting

Pancreatic Neoplasms

NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

360 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06478043 2024-07-08

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

54 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06434090 2024-05-30

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

74 enrolled

Colorectal Neoplasms

NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

120 enrolled

Efficacy and Safety

NCT06370754 2024-04-17

FD-IMPACT

117 enrolled

Pancreatic Neoplasms

NCT06332950 2024-03-27

Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy

80 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06259058 2024-03-15

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

96 enrolled

Pancreatic Neoplasms

NCT06192680 2024-01-18

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

63 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06210360 2024-01-18

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

134 enrolled

Pancreatic Neoplasms

NCT06172036 2023-12-15

CAPT-02

180 enrolled